SCHEMBL4313332

SCHEMBL4313332

COC(=O)c1ccc(CCc2ccccn2)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ MAPT P10636 4/20 0.46
▸ POLB P06746 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ ALOX15 P16050 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ RAB9A P51151 4/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ BDKRB1 P46663 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ RGS12 O14924 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ VNN1 O95497 1/20 0.42
▸ METAP2 P50579 1/20 0.41
▸ PARP10 Q53GL7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4320075 0.84 SMN1; SMN2 (0.50) KMT2AMEN1MAPTPOLBKDM4E
SCHEMBL18424239 0.84 KDM4E (0.43) KMT2AMEN1MAPTPOLBKDM4E
SCHEMBL4315767 0.80 PKM (0.46) KMT2AMAPTPOLBKDM4EALOX15
SCHEMBL4319936 0.80 SYK (0.56) MAPTKDM4EHTTRAB9APKM
SCHEMBL18424240 0.80 HDAC3 (0.47) KMT2AMEN1POLBKDM4EALOX15
SCHEMBL8320040 0.79 ALDH1A1 (0.49) KMT2AMEN1MAPTPOLBKDM4E
SCHEMBL509956 0.79 PKM (0.59) KMT2AMEN1MAPTPOLBKDM4E
SCHEMBL14966988 0.77 MAPT (0.65) KMT2AMEN1MAPTPOLBKDM4E
SCHEMBL31691426 0.77 ALOX15 (0.47) KMT2AMEN1MAPTPOLBKDM4E
SCHEMBL3653076 0.77 DPP4 (0.51) KMT2AMEN1MAPTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566781-B2 Imidazopyridine compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-07-28 — — US disclosed
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide BANYU PHARMACEUTICAL., LTD. (JP) 2007-10-25 — — US disclosed
EP-1748048-A1 IMIDAZOPYRIDINE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide MC1R, MCHR2, MCHR1 KMT2A 555/4885MEN1 517/4885MAPT 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback